Clinical Trials Directory

Trials / Completed

CompletedNCT00233766

Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX)

An Evaluation of Two Reduced Sirolimus Doses on the BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions(REDOX)

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
60 (planned)
Sponsor
Cordis US Corp. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to assess the performance and safety of two reduced sirolimus doses on the Bx VELOCITY Balloon-Expandable stent, mounted on the Raptorâ rapid exchange (RX) Stent Delivery System (SDS) in patients with de novo native coronary artery lesions.

Conditions

Interventions

TypeNameDescription
DEVICEBx VELOCITY Stent containing 45% and 70% of Sirolimus dose

Timeline

Start date
2002-09-01
Primary completion
2007-12-01
Completion
2007-12-01
First posted
2005-10-06
Last updated
2008-04-24

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT00233766. Inclusion in this directory is not an endorsement.

Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX) (NCT00233766) · Clinical Trials Directory